Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

Main Inclusion Criteria (At Screening visit): * Informed consent signed and dated (obtained prior to initiating any procedures). * Patient aged ≥18 years old. * Persistence of dry eye syndrome, despite artificial tears use in the previous month prior to the screening visit Main Exclusion Criteria (At both Screening and Randomisation visits): * Far Best-Corrected Visual Acuity (BCVA) ≥+0.7 LogMar (e.g., ≤0.2 in decimal value or ≤20/100 Snellen equivalent or ≤50 letters Early Treatment Diabetic Retinopathy Study (ETDRS)). * Patient with previous or current ophthalmic condition